Felix Lindberg

Felix Lindberg

Auto-generated profile, based on publicly available information

Felix Lindberg

Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet , Stockholm

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in Circulation
Verified
Journal Article
Closed access
CBChristian Basile
Christian Basile
FLFelix Lindberg
Felix Lindberg
LBLina Benson
Lina Benson
FGFederica Guidetti
Federica Guidetti
UDUlf Dahlström
Ulf Dahlström
GSGianluigi Savarese
Gianluigi Savarese
BACKGROUND: Limited evidence exists on the prognostic role of continuing medical therapy in patients with heart failure (HF) and an ejection fraction (EF) that has improved over time. This study assessed rates of, patient profiles, and associations with morbidity/mortality of renin-angiotensin inhibitors (RASi), angiotensin receptor–neprilysin inhibitors (ARNi), beta-blockers (BBL), and mineralocorticoid receptor antagonists (MRA) withdrawal in patients with HF with improved EF. METHODS: Patients with a first recorded EF <40% and a later EF ≥40% from the Swedish HF registry between June 11, 2000, and December 31, 2023, were included in this retrospective observational study. Withdrawal was defined as a patient on treatment at the first (reduced) but not at the second (improved) registration. The association between withdrawal and time to first cardiovascular mortality/hospitalization for HF with censoring at 1 year was assessed by Cox regression model using overlap weighting. RESULTS: Of 8728 patients with HF with improved EF (median age, 70 years [25th to 75th percentile, 61–78], 2611 [29.9%] women), 96%, 94%, and 46% received RASi/ARNi, BBL, and MRA, respectively, when EF was <40%. The withdrawal rates at the time of the improved EF registration were 4.4% for RASi/ARNi, 3.3% for BBL, and 17.2% for MRA. Predictors of withdrawal included lower use of other HF medications, higher EF at the later EF registration, and a longer time between the 2 EF assessments. After weighting, withdrawal was independently associated with a higher risk of cardiovascular mortality/hospitalization for HF by 38% for RASi/ARNi and 36% for MRA, but not for BBL. Withdrawal of BBL was associated with a higher risk of the primary outcome in the subgroup of patients with an improved EF of 40% to 49% versus ≥50% ( P -interaction 0.03). CONCLUSIONS: In patients with HF with improved EF, HF therapy withdrawal was rare. Withdrawing RASi/ARNi and MRA was associated with higher mortality/morbidity at 1 year. No association was found for BBL withdrawal, albeit with a significant heterogeneity for EF at improvement, suggesting better outcomes with continuing BBL only until EF improves up to 50%. These results are hypothesis-generating and highlight the need for randomized controlled trials testing BBL withdrawal in patients with HF with improved EF.

18 May 2023 in European Heart Journal - Cardiovascular Pharmacotherapy
Verified
Journal Article
Open access
PDF file
DSDavide Stolfo
Davide Stolfo
LLLars H Lund
Lars H Lund
GSGianfranco Sinagra
Gianfranco Sinagra
FLFelix Lindberg
Felix Lindberg
UDUlf Dahlström
Ulf Dahlström
GSGianluigi Savarese
Gianluigi Savarese
Guideline recommendations for the treatment of heart failure with mildly reduced ejection fraction (HFmrEF) derive from small subgroups in post-hoc analyses of randomized trials. We investigated predictors of renin–angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors (RASI/ARNI) and beta-blockers use, and the associations between these medications and mortality/morbidity in a large real-world cohort with HFmrEF. Patients with HFmrEF (EF 40–49%) from the Swedish HF Registry were included. The associations between medications and cardiovascular (CV) mortality/HF hospitalization (HFH), and all-cause mortality were assessed through Cox regressions in a 1:1 propensity score-matched cohort. A positive control analysis was performed in patients with EF < 40%, while a negative control outcome analysis had cancer-related hospitalization as endpoint. Of 12 421 patients with HFmrEF, 84% received RASI/ARNI and 88% beta-blockers. Shared-independent predictors of RASI/ARNI and beta-blockers use were younger age, being an outpatient, follow-up in specialty care, and hypertension. In the matched cohorts, use of both RASI/ARNI and beta-blocker use was separately associated with lower risk of CV mortality/HFH [hazard ratio (HR) = 0.90, 95% confidence interval (CI): 0.83–0.98 and HR = 0.82, 95% CI: 0.74–0.90, respectively] and of all-cause mortality (HR = 0.75, 95% CI: 0.69–0.81 and HR = 0.79, 95% CI: 0.72–0.87, respectively). Results were consistent at the positive control analysis, and there were no associations between treatment use and the negative control outcome. RASI/ARNI and beta-blockers were extensively used in this large real-world cohort with HFmrEF. Their use was safe since associated with lower mortality and morbidity. Our findings confirm the real-world evidence from previous post-hoc analyses of trials, and represent a further call for implementing guideline recommendations. The overall study cohort counted on 12 421 patients with mildly reduced ejection fraction heart failure (HFmrEF). Two sensitivity outcome analyses were adopted, the first conducted on the same population with cancer hospitalization as an outcome (falsification analysis), and the second on 26 143 patients with reduced ejection fraction heart failure (HFrEF). In the upper right panel: use of RASI/ARNI and beta-blockers and percentage of target dose achievement in the overall study population with HFmrEF (n = 12 421). In the bottom panels: Kaplan–Meier curves for the association between RASI/ARNI use (left panel) and the composite outcome (cardiovascular mortality or heart failure hospitalization) and between beta-blockers use (right panel) and the composite outcome. CI, confidence interval; HR, hazard ratio; RASI/ARNI, renin–angiotensin system inhibitors/angiotensin receptor neprilysin inhibitor; TD, target dose.

1 April 2026 in European Heart Journal
Verified
Journal Article
Open access
PDF file
FLFelix Lindberg
Felix Lindberg
AUAlicia Uijl
Alicia Uijl
LBLina Benson
Lina Benson
VVValeria Valente
Valeria Valente
ACAndrew J S Coats
Andrew J S Coats
GSGianluigi Savarese
Gianluigi Savarese
Background and Aims: Real-world uptake of heart failure with reduced ejection fraction (HFrEF) treatments relies on physician prescriptions but also on patient adherence. This study assessed implementation of, patient adherence and persistence with quadruple HFrEF therapy in the contemporary setting, and associations with morbidity/mortality. Methods: Patients with HFrEF enrolled in the Swedish Heart Failure Registry between January 2016 and December 2023 were included. Using pharmacy refills, patients with ≥80% proportion of days covered were categorized as adherent and with dispensations at 12 ± 2 months post-index as persistent. Results: In 35 215 patients with HFrEF [median age 74 (interquartile range 64–80) years; 28% female], use of all four HFrEF foundational therapies increased between 2016 and 2023: in 2023, 93% used beta-blockers (BB), 95% renin–angiotensin–system inhibitors (RASi)/angiotensin receptor–neprilysin inhibitors (ARNi), 73% mineralocorticoid receptor antagonists (MRA), 83% sodium–glucose co-transporter 2 inhibitors (SGLT2i), and 60% quadruple therapy. The proportion of patients who were adherent and persistent, respectively, to BB was 95% and 90%, RASi/ARNi 95% and 89%, MRA 90% and 77%, SGLT2i 94% and 86%, and quadruple therapy 85% and 67%. Good adherence and persistence for BB, RASi/ARNi, and MRA and good adherence for SGLT2i were independently associated with lower heart failure hospitalization/cardiovascular death. Conclusions: By 2023, use of quadruple therapy reached ∼60%, being mostly limited by lower adoption of MRA (∼73%). Patient adherence to foundational therapies was high and appeared associated with better prognosis. These data suggest that improvements in the uptake of and adherence to quadruple HFrEF pharmacotherapy are achievable in real-word heart failure care, although suboptimal dosing and frequent discontinuations remain important areas of further implementation.

4 October 2025 in JACC: Heart Failure
Verified
Journal Article
Open access
FLFelix Lindberg
Felix Lindberg
CCCarin Corovic Cabrera
Carin Corovic Cabrera
LBLina Benson
Lina Benson
ULUlrika Löfström
Ulrika Löfström
KLKrister Lindmark
Krister Lindmark
GSGianluigi Savarese
Gianluigi Savarese
How iron deficiency (ID) is defined in heart failure (HF) may affect ID prevalence, associated prognosis, and achievable intravenous iron benefit. This study assessed 4 definitions of ID in heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), and heart failure with preserved ejection fraction (HFpEF) and evaluated prevalence, associated health-related quality of life (HR-QoL), symptoms, and cause-specific morbidity and mortality. Patients enrolled in the Swedish HF Registry from 2017 to 2023 were included. ID was defined as follows: 1) in current HF guidelines; 2) in the IRONMAN (Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency) trial; 3) with transferrin saturation (TSAT) <20%; and 4) with a ferritin value <100 μg/L. Of 20,673 patients (median age 74 years [Q1-Q3: 65-80 years]; 32% female), 49% fulfilled guideline ID criteria (HFrEF, 48%; HFmrEF, 48%; HFpEF, 54%), 53% fulfilled IRONMAN criteria (HFrEF, 52%; HFmrEF, 52%; HFpEF, 59%), 36% had TSAT <20% (HFrEF, 36%; HFmrEF, 34%; HFpEF, 41%), and 37% has a ferritin level <100 μg/L (HFrEF, 35%; HFmrEF, 37%; HFpEF, 42%). All definitions were independently associated with worse symptoms, and all except ferritin <100 μg/L were associated with worse HR-QoL. TSAT <20% and IRONMAN ID criteria were independently associated with a higher risk of all outcomes, including cardiovascular or all-cause death and HF or all-cause/cardiovascular/noncardiovascular hospitalizations. Guidelines-defined ID was independently associated only with outcomes containing HF hospitalizations or total all-cause hospitalizations, and ferritin <100 μg/L was associated with no outcome. TSAT <20% and IRONMAN ID criteria had stronger associations in HFpEF for outcomes containing HF hospitalization (P interaction < 0.05). TSAT <20% showed the greatest prognostic associations and discrimination. Irrespective of definition, ID was highly prevalent (highest in HFpEF) and independently associated with worse symptoms or HR-QoL. ID defined as TSAT <20% showed the strongest associations with outcomes, including mortality and HF or cardiovascular/noncardiovascular hospitalizations, likely representing the preferred definition with which to enroll a higher-risk group in trials.

14 January 2026 in European Journal of Heart Failure
Verified
Journal Article
Open access
SEIF EL HADIDISEIF EL HADIDI
SEIF EL HADIDI
FLFelix Lindberg
Felix Lindberg
LBLina Benson
Lina Benson
AUAlicia Uijl
Alicia Uijl
DSDavide Stolfo
Davide Stolfo
GSGianluigi Savarese
Gianluigi Savarese
Aims: Patients with heart failure and reduced ejection fraction (HFrEF) are frequently exposed to polypharmacy, placing them at risk of potentially inappropriate prescribing (PIP)—defined as use of drugs that may worsen HF prognosis, counteract guideline-directed medical therapies (GDMTs), or increase harmful interactions. The prevalence, predictors, and prognostic impact of PIP in HFrEF remain unclear. Therefore, the aim was to investigate the prevalence, predictors, and outcomes of PIP in a large, real-world HFrEF population. Methods: Patients with HFrEF enrolled in the Swedish HF Registry (2005–2020) were included. The ESC position statement of PIP-HFrEF was used to retrieve PIP from the National Prescribed Drugs Register. Associations between PIP and outcomes were assessed using Cox proportional hazards and negative binomial regression for recurrent events. Results: Among 50,348 patients (median age 75 years, 29% female), 23,583 (47%) were prescribed ≥1 PIP. The most frequent agents were neuroleptics (29%), systemic steroids (10%), and NSAIDs (6%). Independent predictors included rheumatoid arthritis (OR 3.39; 95%CI 2.92–3.94), depression (OR 3.06; 95%CI 2.74–3.42), chronic obstructive pulmonary disease (OR 1.86; 95%CI 1.76–1.98), and gout (OR 1.48; 95%CI 1.35–1.62). Patients on PIP were less likely to receive GDMT. Presence of ≥1 PIP was independently associated with increased 3-year risk of HF death (HR 1.13; 95%CI 1.04–1.23), all-cause and cardiovascular death, first and recurrent HF hospitalisations. Conclusions: Nearly half of HFrEF patients received PIP medications, particularly those with multimorbidity, which was independently associated with worse outcomes and less GDMT use. Our data underscore the need for targeted strategies to reduce inappropriate prescribing in HFrEF.

19 April 2026 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Open access
GFGiulia Ferrannini
Giulia Ferrannini
FMFrancesca Musella
Francesca Musella
LBLina Benson
Lina Benson
VVValeria Valente
Valeria Valente
FLFelix Lindberg
Felix Lindberg
GSGianluigi Savarese
Gianluigi Savarese
Aims: The aim of this study was to assess the implementation of sodium–glucose co-transporter-2 inhibitors (SGLT2i) use in a real-world heart failure (HF) cohort. Methods and results: Patients from the Swedish HF Registry enrolled 1 September 2022 to 16 December 2024 were included. Characteristics independently associated with SGLT2i use were investigated by multivariable logistic regression models, in the overall cohort and stratified by ejection fraction (EF). Of 24 578 patients (median age [Q1–Q3]:75 [65–81] years, 33% female), 43% had HF with reduced EF(HFrEF), 31% had HF with mildly reduced EF(HFmrEF), and 26% had HF with preserved EF(HFpEF). During the study period, SGLT2i use increased from 78% to 89% in HFrEF, from 54% to 80% in HFmrEF, and from 41% to 80% in HFpEF. Independent predictors of SGLT2i use included male sex, HF hospitalization during the past year, impaired kidney function, obesity, higher socioeconomic profile, and beta-blocker use. Follow-up in specialist care was associated with higher use in HFrEF and HFmrEF. Type 2 diabetes (T2DM) was independently associated with use across EF, with a stronger association in HFpEF. Renin–angiotensin–aldosterone system inhibitors were associated with SGLT2i use across the EF spectrum, with stronger associations in HFrEF and HFmrEF, while mineralocorticoid receptor antagonists showed similar associations across EF categories, stronger in HFrEF and HFmrEF. Conclusion: SGLT2i were rapidly implemented in clinical practice, with their use reaching ∼90% in HFrEF and approaching a plateau at ∼80% in HFmrEF and HFpEF in December 2024. There is still room for treatment optimization, particularly among women, patients with HFpEF without T2DM, those followed in primary care, and with lower socioeconomic status.